{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:40:09Z","timestamp":1772192409957,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Special Project of Pudong New District Health Commission","award":["PW2023E-05"],"award-info":[{"award-number":["PW2023E-05"]}]},{"name":"Key specialty Project of Pudong New District Health Commission","award":["PWZzk2022-22"],"award-info":[{"award-number":["PWZzk2022-22"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04049-w","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:37:04Z","timestamp":1761046624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population"],"prefix":"10.1186","volume":"23","author":[{"given":"Bo","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panwang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"4049_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4049_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"4049_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","volume":"18","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18:282\u2013301.","journal-title":"Nat Rev Urol"},{"key":"4049_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol"},{"key":"4049_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"4049_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with Enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"4049_CR7","doi-asserted-by":"crossref","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399:1695\u2013707.","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"4049_CR8","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol. 2023;41:3595\u2013607.","journal-title":"J Clin Oncol"},{"key":"4049_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015;162:454.","journal-title":"Cell"},{"key":"4049_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"4049_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.6004\/jnccn.2020.7663","volume":"19","author":"B Dong","year":"2021","unstructured":"Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, et al. Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer: a multicenter, real-world study. J Natl Compr Canc Netw. 2021;19:905\u201314.","journal-title":"J Natl Compr Canc Netw"},{"key":"4049_CR12","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345\u201357.","journal-title":"N Engl J Med"},{"key":"4049_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","volume":"8","author":"HB Pearson","year":"2018","unstructured":"Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, et al. Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discov. 2018;8:764\u201379.","journal-title":"Cancer Discov"},{"key":"4049_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131\u201342.","journal-title":"Lancet"},{"key":"4049_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-4939-7717-8_5","volume":"1754","author":"S Chen","year":"2018","unstructured":"Chen S, Liu M, Zhou Y. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data. Methods Mol Biol. 2018;1754:67\u201395.","journal-title":"Methods Mol Biol."},{"key":"4049_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, Wang H, Yu Y, Yang C, Gao X, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580:93\u20139.","journal-title":"Nature."},{"key":"4049_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","volume":"571","author":"EJ Adams","year":"2019","unstructured":"Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571:408\u201312.","journal-title":"Nature"},{"key":"4049_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/JU.0000000000001363","volume":"205","author":"L Fan","year":"2021","unstructured":"Fan L, Fei X, Zhu Y, Pan J, Sha J, Chi C, Gong Y, Du X, Zhou L, Dong B, et al. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing. J Urol. 2021;205:461\u20139.","journal-title":"J Urol."},{"key":"4049_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating tumor DNA genomics correlate with resistance to Abiraterone and Enzalutamide in prostate cancer. Cancer Discov. 2018;8:444\u201357.","journal-title":"Cancer Discov"},{"key":"4049_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2020","unstructured":"Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2020;77:14\u201321.","journal-title":"Eur Urol"},{"key":"4049_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","volume":"20","author":"AM Lee","year":"2022","unstructured":"Lee AM, Saidian A, Shaya J, Nonato T, Cabal A, Randall JM, et al. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin Genitourin Cancer. 2022;20:515\u201323.","journal-title":"Clin Genitourin Cancer"},{"key":"4049_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eururo.2019.09.036","volume":"77","author":"MA Reimers","year":"2020","unstructured":"Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, et al. Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur Urol. 2020;77:333\u201341.","journal-title":"Eur Urol"},{"key":"4049_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.527","volume":"11","author":"X Fei","year":"2021","unstructured":"Fei X, Fan L, Chen W, Chen W, Gong Y, Du X, et al. The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: a real-world multicenter study. Clin Transl Med. 2021;11:e527.","journal-title":"Clin Transl Med"},{"key":"4049_CR24","doi-asserted-by":"crossref","unstructured":"Dana ER, Kim NC, David O, Heather HC, Neeraj A, Julie NG, Shahneen KS, Vinny H, Angela LG, Peter JF, Gerhardt At: AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). JCO 39, TPS176-TPS176, 2021.","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS176"},{"key":"4049_CR25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41391-020-00302-3","volume":"24","author":"Z Liu","year":"2021","unstructured":"Liu Z, Guo H, Zhu Y, Xia Y, Cui J, Shi K, et al. TP53 alterations of hormone-na\u00efve prostate cancer in the Chinese population. Prostate Cancer Prostatic Dis. 2021;24:482\u201391.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4049_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","volume":"78","author":"U Swami","year":"2020","unstructured":"Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol. 2020;78:652\u20136.","journal-title":"Eur Urol"},{"key":"4049_CR27","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","volume":"24","author":"G Boysen","year":"2018","unstructured":"Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, et al. SPOP-mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity. Clin Cancer Res. 2018;24:5585\u201393.","journal-title":"Clin Cancer Res"},{"key":"4049_CR28","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1200\/JCO.2023.41.16_suppl.5059","volume":"41","author":"O Ifeanyichukwu","year":"2023","unstructured":"Ifeanyichukwu O, Sachin D, Sharon W, Joanne X, Phillip W, Umang S, Matthew JO, Neeraj A, Rana RM, Chadi N, et al. Characterizing the molecular landscape of early onset and average onset prostate cancer. JCO. 2023;41:5059\u20135059.","journal-title":"JCO"},{"key":"4049_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41585-023-00827-x","volume":"21","author":"JO Mori","year":"2024","unstructured":"Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, et al. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nat Rev Urol. 2024;21:258\u201373.","journal-title":"Nat Rev Urol"},{"key":"4049_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nm.3830","volume":"21","author":"R Malik","year":"2015","unstructured":"Malik R, Khan AP, Asangani IA, Cie\u015blik M, Prensner JR, Wang X, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21:344\u201352.","journal-title":"Nat Med"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04049-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:37:05Z","timestamp":1761046625000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4049"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04049-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shanghai Pudong New Area Zhoupu Hospital (Approved Number: ZPYYLL-2018-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}